T1	total-participants 379 382	235
T2	eligibility 383 418	patients with HER2-positive disease
T3	intervention 438 479	neoadjuvant trastuzumab plus chemotherapy
T5	control 598 628	neoadjuvant chemotherapy alone
T6	total-participants 649 652	228
T7	intervention-participants 689 692	115
T8	control-participants 736 739	113
T4	outcome 1461 1492	breast conserving surgery (BCS)
T9	iv-bin-percent 1494 1497	23%
T10	cv-bin-percent 1505 1508	13%
T11	outcome-Measure 1357 1376	event-free survival
